HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buchanan, T. A. Articles by Watanabe, R. Search for Related Content PubMed PubMed Citation Articles by Buchanan, T. A. Articles by Watanabe, R. Social Bookmarking                What's this?

What Is Gestational Diabetes?

¹ Departments of Medicine, Obstetrics and Gynecology, and Physiology and Biophysics, University of Southern California Keck School of Medicine, Los Angeles, California
² Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California
³ Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center, Torrance, California

Address correspondence and reprint requests to Thomas A. Buchanan, MD, Rm. 6602 GNH, 1200 N. State St., Los Angeles, CA 90089-9317. E-mail: buchanan@usc.edu

Abbreviations: DPP, Diabetes Prevention Program • GDM, gestational diabetes mellitus • PIPOD, Pioglitazone in Prevention of Diabetes • TRIPOD, Troglitazone in Prevention of Diabetes

The first 300 words of the full text of this article appear below.

	INTRODUCTION

 
Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition during pregnancy. As such, GDM is the product of routine glucose tolerance screening that is currently carried out in otherwise healthy individuals. Like other forms of hyperglycemia, GDM is characterized by pancreatic ß-cell function that is insufficient to meet the body's insulin needs. Available evidence suggests that ß-cell defects in GDM result from the same spectrum of causes that underlie hyperglycemia in general, including autoimmune disease, monogenic causes, and insulin resistance. Thus, GDM often represents diabetes in evolution and, as such, holds great potential as a condition in which to study the pathogenesis of diabetes and to develop and test strategies for diabetes prevention.

	DETECTION: POPULATION SCREENING FOR GLUCOSE INTOLERANCE—

 
The clinical detection of GDM is accomplished in different ways in different countries. In general, the approaches apply one or more of the following procedures: 1) clinical risk assessment, 2) glucose tolerance screening, and 3) formal glucose tolerance testing. The procedures are applied to pregnant women not already known to have diabetes. Controversies regarding the optimal methods for detecting GDM are beyond the scope of this article. The relevant point is that the screening for GDM is the only standard medical practice that applies screening for glucose intolerance to otherwise healthy individuals. Regardless of the glucose thresholds that are used to diagnose GDM, the patients are relatively young individuals whose glucose levels are in the upper end of the population distribution during pregnancy. A small minority of those women have glucose levels that would be diagnostic of diabetes outside of pregnancy. The large majority have lower glucose levels when they are diagnosed with GDM, but they are at high risk for developing diabetes after pregnancy. Together, patients with GDM offer an important opportunity to study the evolution of diabetes . . . [Full Text of this Article]

	GLUCOSE REGULATION IN PREGNANCY AND GDM—

 
GDM on background of chronic insulin resistance
GDM and autoimmune ß-cell dysfunction
GDM and monogenic diabetes

	GDM: AN OPPORTUNITY FOR THE STUDY OF EVOLVING DIABETES AND FOR DIABETES PREVENTION—

 

	SUMMARY AND FUTURE DIRECTIONS—

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. L. Exelbert A Comparison Between a "Terror" Reaction and a "Nonchalant" Reaction to the Diagnosis of Gestational Diabetes Clin. Diabetes, October 1, 2008; 26(4): 177 - 178. [Full Text] [PDF]

				S. Kidambi and S. B. Patel Diabetes Mellitus: Considerations for Dentistry J Am Dent Assoc, October 1, 2008; 139(suppl_5): 8S - 18S. [Abstract] [Full Text] [PDF]

				J. E. Friedman, J. P. Kirwan, M. Jing, L. Presley, and P. M. Catalano Increased Skeletal Muscle Tumor Necrosis Factor-{alpha} and Impaired Insulin Signaling Persist in Obese Women With Gestational Diabetes Mellitus 1 Year Postpartum Diabetes, March 1, 2008; 57(3): 606 - 613. [Abstract] [Full Text] [PDF]